The operating result amounted to CHF 39.5 million (2024: CHF 31.9 million). The operating profit margin was 10.3% (2024: 8.5%).
2025 was a year for Mikron that tested the resilience of the group while confirming the strength of its strategic direction. Overall, order intake decreased compared to the previous year – a result of the more cautious investment climate in several industries and regions. Nevertheless, Mikron achieved stable operational performance, advanced key strategic initiatives, and remains in a good financial position. With an operating profit margin of 10.3%, the group exceeded its profitability target and achieved net sales of CHF 381.9 million. This demonstrates Mikron's operational strength and highlights the value created for customers. The business model is robust and well-prepared for the future.
Order intake and order backlog
Mikron's order intake in 2025 was CHF 332.7 million, which is 14.4% lower than the previous year's figure. The Automation business segment contributed CHF 232.2 million to the order intake, representing a decline of 12.4%. In the USA, order intake fell short of expectations, primarily due to extended decision-making processes among customers and project delays in the pharmaceutical and medical technology sectors. Machining Solutions ended the year with an order intake of CHF 100.7 million, which corresponds to a decrease of 18.6%. The decline was most pronounced in Europe, where the industry continued to invest very cautiously. Ongoing geopolitical uncertainties and US tariffs on certain goods intensified the pressure and delayed customers' investment decisions.
Net Revenue
Mikron's net sales amounted to CHF 381.9 million, representing an increase of 2.1% compared to the previous year. However, the appreciation of the Swiss franc reduced net sales by 2.0%. The pharmaceutical and medical technology industry accounted for 66% (2024: 61%) of net sales, an increase of 11.0% compared to the previous year. These sectors are also the main growth drivers for Mikron.
Net sales in the Automation business segment were CHF 250.1 million, an increase of 7.2% compared to the previous year. 97% of net sales came from the pharmaceutical and medical technology industry (2024: 94%). In Europe, Automation recorded continued strong growth of 13.2%, which was partially offset by declines in North America (-29.0%) and Asia (-21.1%).
Net sales of Machining Solutions decreased by 6.2% to CHF 132.0 million. While North America grew by 21.6%, sales in Europe fell by 12.7% and in Asia by 9.8%. In response to this and to increase efficiency and competitiveness, the business segment will implement a cost reduction program and expand its production and operational sites. At the same time, Machining Solutions achieved further technological advancements, particularly in high-precision machining platforms and digital service offerings. This positions Mikron well for the changing demands of the industry.
Profitability
Mikron's operating profit in 2025 was CHF 39.5 million or 10.3% of net sales, compared to CHF 31.9 million or 8.5% of net sales in the previous year. The main reason for the increase in operating profit lies in the sales growth of Automation in Europe and capacity adjustments in the USA.
Distribution to Shareholders
Towards the end of 2025, Mikron experienced a decline in order intake in both business segments. While the group expects the decline for Automation to be only temporary, Machining Solutions is burdened by a persistent general market weakness, making a turnaround difficult to predict. Therefore, Mikron forecasts net sales for 2026 in the range of CHF 340 to 380 million with an operating profit margin of 7 to 10%.
Contact:
